SCM
Soleus Capital Management Portfolio holdings
AUM
$1.45B
This Quarter Return
+7.62%
1 Year Return
+18.23%
3 Year Return
+274.85%
5 Year Return
+440.77%
10 Year Return
–
AUM
$993M
AUM Growth
+$993M
(+10%)
Cap. Flow
+$136M
Cap. Flow
% of AUM
13.75%
Top 10 Holdings %
Top 10 Hldgs %
39.81%
Holding
126
New
24
Increased
29
Reduced
26
Closed
35
Top Buys
| 1 |
GSK
GSK
|
$34.2M |
| 2 |
Treace Medical Concepts
TMCI
|
$25M |
| 3 |
TG Therapeutics
TGTX
|
$20.5M |
| 4 |
Insulet
PODD
|
$20.4M |
| 5 |
Teva Pharmaceuticals
TEVA
|
$18.4M |
Top Sells
| 1 |
Charles River Laboratories
CRL
|
$22.2M |
| 2 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$13.7M |
| 3 |
Arcellx
ACLX
|
$12.9M |
| 4 |
CVS Health
CVS
|
$11.3M |
| 5 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
$9.95M |
Sector Composition
| 1 | Healthcare | 98.3% |
| 2 | Consumer Staples | 1.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
89bio
ETNB
$1.35B
| $5.34M | 0.49% |
346,033
+119,533
| +53% | +$1.85M |
|
52
UroGen Pharma
URGN
$879M
| $5.21M | 0.48% |
+372,000
| New | +$5.21M |
|
53
Acadia Pharmaceuticals
ACAD
$4.29B
| $5.1M | 0.47% |
244,627
+178,627
| +271% | +$3.72M |
|
|
THTX
54
Theratechnologies
THTX
$149M
| $5.01M | 0.46% |
+2,331,376
| New | +$5.01M |
|
55
C4 Therapeutics
CCCC
$182M
| $5.01M | 0.46% |
2,692,020
| – | – |
|
56
Castle Biosciences
CSTL
$682M
| $4.79M | 0.44% |
+283,500
| New | +$4.79M |
|
57
InspireMD
NSPR
$99.7M
| $4.51M | 0.42% |
1,378,128
| – | – |
|
58
Tarsus Pharmaceuticals
TARS
$2.42B
| $4.44M | 0.41% |
+250,000
| New | +$4.44M |
|
59
Seres Therapeutics
MCRB
$171M
| $4.33M | 0.4% |
1,820,983
-225,000
| -11% | -$536K |
|
60
Mirum Pharmaceuticals
MIRM
$3.74B
| $3.25M | 0.3% |
103,000
-73,000
| -41% | -$2.31M |
|
61
Applied Therapeutics
APLT
$74.7M
| $2.97M | 0.27% |
+1,192,626
| New | +$2.97M |
|
62
Biohaven
BHVN
$1.67B
| $2.96M | 0.27% |
+113,800
| New | +$2.96M |
|
63
GeneDx Holdings
WGS
$3.69B
| $2.84M | 0.26% |
781,396
+70,000
| +10% | +$255K |
|
64
Kiniksa Pharmaceuticals
KNSA
$2.56B
| $2.73M | 0.25% |
157,349
-362,291
| -70% | -$6.29M |
|
65
Natera
NTRA
$23B
| $2.72M | 0.25% |
61,377
-107,423
| -64% | -$4.75M |
|
66
Design Therapeutics
DSGN
$335M
| $2.42M | 0.22% |
+1,025,000
| New | +$2.42M |
|
67
Lyra Therapeutics
LYRA
$11.8M
| $2.32M | 0.21% |
592,417
| – | – |
|
68
Praxis Precision Medicines
PRAX
$976M
| $1.97M | 0.18% |
1,150,000
-950,000
| -45% | -$1.62M |
|
69
Xenon Pharmaceuticals
XENE
$3B
| $1.78M | 0.16% |
52,000
-14,000
| -21% | -$478K |
|
70
Syndax Pharmaceuticals
SNDX
$1.37B
| $1.74M | 0.16% |
119,500
-93,100
| -44% | -$1.35M |
|
|
WHWK
71
Whitehawk Therapeutics, Inc. Common Stock
WHWK
$85.3M
| $1.61M | 0.15% |
333,227
| – | – |
|
72
4D Molecular Therapeutics
FDMT
$294M
| $1.58M | 0.15% |
123,748
-95,400
| -44% | -$1.21M |
|
73
Alkermes
ALKS
$4.98B
| $1.52M | 0.14% |
54,400
-140,000
| -72% | -$3.92M |
|
74
Viking Therapeutics
VKTX
$3.08B
| $1.35M | 0.12% |
122,200
-214,500
| -64% | -$2.37M |
|
75
Annexon
ANNX
$225M
| $1.22M | 0.11% |
515,400
-105,000
| -17% | -$248K |
|